Kornimate/medical-research-clean huggingface dataset:
sugammadex compared with neostigmin/atropin for neuromuscular block reversal in patients with obstructive sleep apnea

Conditions: Obstructive Sleep Apnea

Summary: incomplete recovery of neuromuscular function after surgery can lead to respiratory complications. patients with obstructive sleep apnea (osa) are prone to respiratory complications after surgery. neostigmin and sugammadex are used for neuromuscular reversal. the aim of this study was to compare sugammadex and neostigmin regarding efficacy, incidence of respiratory complications and cost in patients undergoing surgery for osa

this prospective double blind controlled study will be conducted after obtaining informed written patient consent. simple randomization will be accomplished with a computer-generated sequence of numbers and sealed envelopes will be used to allocate patients into 2 groups. group n will receive 50 µg kg-1 neostigmin,+05 mg atropin group s will receive sugammadex 2mg kg-1 sugammadex at the and of surgery. patients will enter the operation room without receiving premedication heart rate, noninvasive blood pressures, body temperature, bis, end-tidal respiratory gases and neuromuscular function (acceleromyography) will be monitored propofol will be used for anesthesia induction rocuronium 0.6 mg kg-1 will be used to facilitate intubation anesthesia will be maintained with sevoflurane in oxygen and nitrous oxide, bis will be maintainen between 40-60 additional rocuronium doses will be administered when the tof t2 is observed at the end of surgery, volatile anesthesia will be discontinued, the study drug will be administered according to group allocation and the tof response at this time will be recorded time to obtain tof0.9 will be recorded time to extubation, time to recovery, time spent in the operation room will be recorded respiratory and cardiovascular complications (bradycardia, tachycardia, hypertention, ritmia, bronchospasm, laringospasm, breath holding, cough, desaturation, hypoxia, nimv, reintubation) and treatments during anesthesia emergence will be recorded patients will be transfered to the pacu, time spent in pacu and respiratory and cardiovascular complications (bradycardia, tachycardia, hypertention, ritmia, bronchospasm, laringospasm, breath holding, cough, desaturation, hypoxia, nimv, reintubation) and treatments during pacu stay will be recorded after achieving an aldrete score \>9 patients will be transfered to the ward. patients who can not achieve aldrete score \>9 after 1 hour will be transfered to the icu. respiratory and cardiovascular complications and treatments in the icu will be recored

Eligibility criteria:
inclusion criteria: asa i-iii schedulled for surgery for obstructive sleep apnea - exclusion criteria: neurouscular disorders hepatic or renal dysfunction allergy to study drugs using medication that could interfere with nmbas pregnancy breasth feeding -

Keywords: sugammadex neostigmine obstructive sleep apnea
xeomin® and gait related mobility after stroke

Conditions: Stroke

Summary: the aim of the present pilot study is to evaluate the association between change in gait related mobility in ambulatory male and female adult hemiparetic patients before and 4-6-weeks after xeomin® injection into the upper limb, using two standardized tests of physical function in outpatient rehabilitation that are widely used; the 10-meter walk test and the timed 'up and go' test (tug).

for this pilot study, the investigators hypothesize that there will be durational improvements in gait related mobility on the instrumented tug and 10-meter walk tests 4-6-weeks post upper extremity xeomin® injection. physical function will be quantified as time to complete the instrumented tug. a one-group pretest-post-test experimental design will be used. participants will be tested on the primary and secondary outcome measures before upper extremity injection with xeomin® and 4 to 6 weeks thereafter. additionally, participants will be contacted for an end of study visit via telephone approximately 12-weeks post xeomin® injection to obtain information regarding any adverse events and gain insight into the therapeutic duration of the xeomin®. the proposed duration of the study is 2 years to allow adequate time for screening, recruitment and follow-up.

Eligibility criteria:
inclusion criteria: * diagnosis of hemiparesis and spasticity secondary to stroke with upper and lower limb spasticity and unilateral motor and/or sensory deficit * no prior surgery to the lower limb * able to walk at least 10 meters without physical assistance from another person and without an assistive device * toe- ground clearance during swing phase without assistive device or orthoses * no treatment with botulinum toxin within the past 4 months exclusion criteria: * passive range of motion at either the ankle, knee, or elbow joint less than 30 degrees * participants with uncorrected hearing impairment * weight bearing restrictions due to concurrent orthopedic injuries that would make ambulating with or without an assistive device unsafe * speech language expression deficit (e.g., aphasia) * absence of proprioception upon neurologic examination * presence of fixed contractures in the upper or lower extremities not correctable to neutral * other confounding neurological diagnoses or active acute illness (cancer, parkinson's disease, multiple sclerosis)
glycosylated hemoglobin and risk of perioperative major cardiovascular events in diabetic patients undergoing coronary bypass revascularization (hba1c)

Conditions: Cardiovascular Event; Coronary Artery Bypass Graft; Diabetes Mellitus

Summary: glycosylated hemoglobin (hba1c) is considered as one of the best markers to assess the glycaemia treatment over a period of 3 to 4 months, and is considered as predictive marker for perioperative mortality and morbidity. the impact of the elevated hba1c on the risk of perioperative major cardiovascular events in patients undergoing coronary bypass revascularization (by retrospective analysis of perioperative cardiovascular events and preoperative hba1c) is evaluated.


Eligibility criteria:
inclusion criteria: * patients with diabetes mellitus undergoing coronary bypass revascularization since 2012 exclusion criteria: * disapproval of use of data for research purposes
visual outcome, cylinder correction and patient satisfaction after implantation of at lisa tri toric 939mp intraocular lenses

Conditions: Cataract

Summary: the aim of the present study is to evaluate the postoperative visual acuity for distance, intermediate and near vision as well as the cylinder correction and the patient satisfaction after bilateral implantation of at lisa tri toric 939mp iols.


Eligibility criteria:
inclusion criteria: * patient informed of the consequences and constraints of the protocol and who has given his/her written informed consent * man or woman, over 50 years of age * healthy eyes with bilateral cataract requiring surgical treatment for both eyes * bilateral regular corneal astigmatism (confirmed by topography measurement) * only patients requiring intraocular lenses of a power comprised between sphere +0.0 and +28.0 dioptres and between a cylindrical range of +1.0 to +4.0d in both eyes will be able to participate in the trial. * biometry measurement/cataract density compatible with the iolmaster evaluation * bilateral uncomplicated cataract surgery and implantation into capsular bag by injector * assured follow-up examinations exclusion criteria: * patients unable to meet the limitations of the protocol or likely of non cooperation during the trial, * patients whose freedom is impaired by administrative or legal order, * monophtalmic patient. * previous ocular surgery, including corneal/refractive surgery, * chronic or recurrent uveitis, * acute ocular disease or external/internal infection, * any kind of macular degeneration and impairment of retina (clinical diagnosis/oct examination) * diabetes with retinal changes, * pseudoexfoliation syndrome * pathologic myosis * irregular astigmatism, especially keratoconus, * endothelial corneal dystrophy * glaucoma or iop higher than 21mmhg under ocular hypertension treatment * aniridia * pseudophakia * cornea guttata; keratoplasty * amotio operation; anamnesis with vitreous surgery * amblyopia * intraocular tumours; endotamponade * phlogistic intraocular processes or other pre-existing processes that permanently limit the best corrected visual acuity to \> 0.3 logmar * any other pathology or condition presenting, according to the investigator opinion, a risk for the patient * pupil diameter over 6 mm in mesopic condition * corneal opacity
safety and efficacy study of umbilical mesenchymal stem cells for liver cirrhosis

Conditions: Liver Cirrhosis

Summary: liver cirrhosis and subsequent liver failure are leading causes of morbidity and mortality worldwide. alcohol abuse and viral hepatitis are the most common causes of cirrhosis. novel therapies are necessary to prevent or block the process of the disease. in this current prospective cohort, the investigators plan to organize four hospitals to determine the safety and efficacy of intravenous administration of umbilical mesenchymal stem cells in the treatment of patients with liver cirrhosis in next three years.


Eligibility criteria:
inclusion criteria: * written informed consent * aged 30-60 years * clinical diagnosis of compensated or decompensated liver * child-pugh b/c (7-12 points) * expecting lifetime is over three years exclusion criteria: * pregnant woman * patient with severe vascular diseases * patient with any organ failure * patient with any tumors * patient with hiv * patient who has been transplanted * patient treated with immunosuppressors * patient for whom the follow-up is considered impossible * patients with any disease or condition which the investigator or treating physician feels would interfere with the trial or the safety of the subject

Keywords: umbilical mesenchymal stem cells; liver cirrhosis
an exploratory study on the safety and effectiveness of paliperidone in patients with schizophrenia

Conditions: Schizophrenia

Summary: the purpose of this study is to assess the safety, effectiveness, and plasma concentration of paliperidone (an antipsychotic medication) given once daily in the treatment of patients with schizophrenia

paliperidone is an extended-release tablet. paliperidone is an active metabolite of risperidone, not approved for the treatment of schizophrenia in japan. this is a multicenter, open-label, parallel-group, fixed dose study to evaluate the safety, effectiveness, and plasma concentration of paliperidone taken once daily in patients with schizophrenia. the patients will receive a fixed dose of paliperidone (3, 9, and 15 mg) for 6 weeks and its effectiveness and safety will be observed for an additional 2 weeks.. efficacy will be measured by determining changes throughout the study in the positive and negative syndrome scale (panss) score, a scale for the measurement of symptoms of schizophrenia, and the clinical global impression (cgi) score. in addition, the study also assesses the relationship between dose/plasma drug concentration and dopamine d2 receptor occupancy in patients who consent to receive positron emission tomography (pet). safety evaluations (symptoms, physical exams, electrocardiograms, laboratory tests, drug-induced extrapyramidal symptoms scale \[diess\] results, and adverse event monitoring) will be conducted throughout the study. the study hypothesis is that paliperidone will be effective in the treatment of schizophrenia, and that it will be well-tolerated. the patients will receive either 3, 9, or 15 mg of paliperidone, taken once daily by mouth for 6 weeks.

Eligibility criteria:
inclusion criteria: * patients diagnosed with schizophrenia according to the diagnostic criteria of dsm-iv * taking not more than one oral antipsychotic medication within 28 days of study entry * a score below 120 at pre-treatment on the positive and negative syndrome scale score (panss), a scale for the measurement of symptoms of schizophrenia exclusion criteria: * diagnosis of psychiatric disease other than schizophrenia according to the diagnostic criteria of dsm-iv * history of parkinson's disease, seizure disorder, cerebrovascular accident, diabetes mellitus, clinically significant gastrointestinal disorders, or severe impairment of the liver or kidneys * drug allergy or hypersensitivity to antipsychotics

Keywords: schizophrenia risperidone positive and negative syndrome scale (panss) clinical global impression (cgi) positron emission tomography (pet)
safety and performance of princess® filler for the treatment of facial lipoatrophy, asymmetry or scars

Conditions: Facial Lipoatrophy; Morphological Asymmetry of the Face; Debilitating Scars

Summary: in this study, eligible patients with the medical indications (facial lipoatrophy, morphological asymmetry of the face, or debilitating scars) will be treated with princess® filler, and then will return for follow-up assessments 2, 4 and 24 weeks after the treatment. a touch-up treatment may be done 2 weeks after the treatment.


Eligibility criteria:
inclusion criteria: * male or female 18 years of age or older. * presence of a defect, which in the opinion of the investigator can be corrected by a dermal filler, and is caused by: ° facial lipoatrophy of moderate severity, or * morphological asymmetry of the face, or * one or more debilitating scars on the face. * willingness to abstain from any cosmetic or surgical procedures in the treatment area for the duration of the clinical investigation. * willingness to take part in the clinical investigation as evidenced by a personally signed informed consent. exclusion criteria: * pregnancy, breastfeeding, or unwillingness to use contraception throughout the clinical investigation (for women of child-bearing potential only). * history of allergic reaction or hypersensitivity to hyaluronic acid. * history or presence of any autoimmune or connective tissue disease, or current treatment with immune therapy. * presence of silicone implant or other non-absorbable tissue filler in the area targeted for intervention, or pre-treatment with any hyaluronic acid filler within the last 6 months. * presence of infectious, inflammatory, or proliferative lesions in the area targeted for intervention. * treatment with anticoagulant or antiplatelet drugs * any disease or condition which, in the investigator's opinion, represents a safety risk for participation in the study * current participation in another clinical trial, or previous treatment with any investigational drug/device within 30 days prior to enrolment * institutionalized persons with legally limited civil rights
examining macrophage influx and vascularization in chronic pancreatitis

Conditions: Pancreatitis; Diabetes

Summary: our aim in this study is to find out if we can locate the similar reduction in the recruitment of macrophages, remodeling of vasculature and do they correlate in the number and area of the islets in pancreas as in the mouse model.


Eligibility criteria:
inclusion criteria: * pancreas tissue sections from preparates from pancreatic surgery. * patients having chronic pancreatitis with or without diabetes
antibiotic therapy for early onset neonatal sepsis

Conditions: Early Onset Neonatal Sepsis

Summary: antibiotic therapy for early onset neonatal sepsis recommended by international guidelines and relevant studies is only kind of treatment regimen that penicillin g/ penicillin/ampicillin combined with gentamicin as the first-line treatment regimen. however, it is not applicable to the clinical practice in many countries and regions. we aim to study efficacy and safety of antibiotics in the treatment of early onset neonatal sepsis.


Eligibility criteria:
inclusion criteria: * age: postnatal age ≤ 72h; * meets nice guidelines for using antibiotics to treat eons; * azlocillin used as part of antimicrobial treatment; * parental written consent. exclusion criteria: * expected survival time less than the treatment cycle; * major congenital malformations; * undergoing surgery within the first week of life; * receiving other systemic trial drug therapy; * other factors that the researcher considers unsuitable for inclusion.
glucose metabolism in the immediate and short term follow up after bariatric surgery

Conditions: Diabetes; Gastric Bypass

Summary: midas involves an assessment of glucose levels obtained before and after bariatric surgery. there are two different procedural tests involved; an oral glucose tolerance test (mixed meal) and a hyperglycemic clamp test. two tests are performed preoperatively and five more are performed postoperatively for a one year period. the associated labwork drawn with the mixed meal and clamp tests are demonstrating changes in glucose, insulin and gut hormone levels.

tests performed are the mixed meal tolerance test, the hyperglycemic clamp test, c-peptide, free fatty acids, adipocyte hormone profile levels.

Eligibility criteria:
inclusion criteria: * negative pregnancy test if female * ada criteria for diabetes type ii * hematocrit \> 35 creatinine \< 1.9, ast \< 3x upper limit of normal, alt \< 3x upper limit of normal, alkaline phos \<3x upper limit of normal * eligibility for bariatric surgery based on the nih and clinical criteria * mentally and legally capable of providing consent exclusion criteria: * lactating females * must not have type i diabetes * systemic steroids taken within 6 months * clinically significant heart disease * recent pulmonary embolism, untreated proliferative retinopathy, renal failure, uncontrolled hypertension, autonomic neuropathy, resting heart rate \> 100, neuromuscular or musculoskeletal disease.

Keywords: diabetes midas gut hormones gastric bypass lap band
a randomized controlled trial investigating if antibiotic use in the first 48 hours of life adversely impacts the preterm infant microbiome

Conditions: Premature Birth of Newborn; Enterocolitis, Necrotizing

Summary: the purpose of this study is to determine whether antibiotics given immediately after birth alter the development of the developing preterm infant's microbiome, which may further alter overall clinical outcomes.


Eligibility criteria:
inclusion criteria for antibiotic randomization: 1. infant must be born between the gestational ages of 28 0/7 weeks and 34 6/7 weeks -and- 2. infant must be born at investigator's home institution. -and- 3. infant must be considered to have a low risk of infection by one of the following criteria: 1. delivered for maternal indications (cesarean section or induction of labor for maternal health, including pre-eclampsia, placental abruption, history of intrauterine fetal demise (iufd)/abruption, multiple gestation requiring preterm delivery, etc) -or- 2. delivered due to preterm labor to a mother without the diagnosis of chorioamnionitis/maternal fever or prolonged rupture of membranes \>18 hours exclusion criteria for antibiotic randomization: 1. signs of clinical illness within the first 3 hours of life: 1. 5-minute apgar \<5 2. requiring vasoactive drugs 3. seizures 4. significant respiratory distress requiring supplemental oxygen \>40% 2. immature:total (i:t) ratio of \>0.2 on initial complete blood count (cbc) 3. congenital anomalies, including renal anomalies requiring serum antibiotic level monitoring any infant born between the gestational ages of 28 0/7 weeks and 34 6/7 weeks who do not meet inclusion criteria, with parental consent, can participate in the stool analysis only arm of the study.

Keywords: microbiome antibiotics
effects of red ginseng on liver function

Conditions: Liver Dysfunction

Summary: korea red ginseng (krg) has effect on liver function

korea red ginseng (krg) has been known as a natural product with anti-inflammatory effect in liver disease. gut microbiota plays an important roles in the pathophysiology of nonalcoholic statohepatitis (nash). we evaluated the effect of krg on the pathophysiology of nash

Eligibility criteria:
inclusion criteria: * ast or alt level \> 50 iu/l exclusion criteria: * viral hepatitis * alcoholic hepatitis * autoimmune hepatitis * pancreatitis * hemochromatosis * wilson's disease * drug induced liver injury * cancer

Keywords: ginseng liver
support, health, and fibromyalgia

Conditions: Fibromyalgia; Quality of Life

Summary: this study tests the effects of social support and education on the health and well-being of people with fibromyalgia (fms). we recruited 600 adults with a confirmed diagnosis of fms from a large health maintenance organization. we randomly assigned the study participants to one of three groups. people in the social support group met with others who suffer from fms for 2 hours every week for 10 weeks, and then monthly for an additional 10 months. the social support and education group also had 10 2-hour weekly meetings followed by 10 monthly meetings with others who suffer from fms. members of this group learned about the disease and ways they can manage it themselves. the third group participated only in the five assessment periods. the study lasted 4 years.

next to osteoarthritis, fms is the most common arthritis-related disease. symptoms include musculoskeletal pain, fatigue, headaches, irritable bowel syndrome, morning stiffness, and sleep disturbances. fluctuating severity, pain, and frustration with the difficulty of diagnosis and treatment lead patients to continually seek help from health care professionals. there is no known cause or cure for this disease. this study tests the effects of social support and education on the health and well-being of people with fibromyalgia (fms). we recruited 600 adults with a confirmed diagnosis of fms from a large health maintenance organization. to be eligible, people had to meet the american college of rheumatology guidelines for fms. after we confirmed the diagnosis, we assigned those who agreed to participate to one of three groups. the first group (social support) met with others who suffer from fms for 2 hours every week for 10 weeks, and then monthly for an additional 10 months. the second group (social support and education) also had 10 2-hour weekly meetings followed by 10 monthly meetings with others who suffer from fms, and its members learned about the disease and self-management techniques. the third group (control) participated only in the five assessment periods. we assessed people in all three groups before we assigned them to a group, after the intervention, and at yearly follow-ups. the study duration was 4 years.

Eligibility criteria:
inclusion criteria: * a diagnosis of fibromyalgia documented in medical records and confirmed using the american college of rheumatology criteria for classification of fms: (1) a history of widespread pain (pain on both sides of the body, above and below the waist, and present for at least 3 months). (2) pain in 11 or more of 18 tender-point sites. * patient willing to attend 10 weekly meetings and 10 monthly meetings. exclusion criteria: * patients who do not meet acr criteria for fms described above. * patients who cannot attend meetings once a week for 10 weeks and once a month for 10 months were excluded.

Keywords: fibromyalgia health education program evaluation social support managed care quality of well-being